抗VEGF药物治疗糖尿病性黄斑水肿的 研究进展
Research Advances in Anti-VEGF Therapy for Diabetic Macular Edema
DOI: 10.12677/acm.2026.1672647, PDF,   
作者: 孔越遆*：华北理工大学研究生院，河北 唐山；唐山市工人医院眼科，河北 唐山；刘 荣#：唐山市工人医院眼科，河北 唐山
关键词: 抗VEGF药物；糖尿病性黄斑水肿；血管内皮生长因子；信号通路；Anti-VEGF Drugs； Diabetic Macular Edema； Vascular Endothelial Growth Factor； Signaling Pathways
摘要: 糖尿病视网膜病变(DR)作为世界第一大致盲性眼底疾病，发病率仍在不断上升，严重影响患者的视觉和生活质量。糖尿病黄斑水肿(DME)是DR患者视力受损的主要原因，具有复杂的病理生理机制，其中血管内皮生长因子(VEGF)在DR与DME的发病机制中起着举足轻重的作用。因此，探索应用抗VEGF药物的最新发展尤为重要。本文旨在叙述近年来抗VEGF药物在DME治疗中的研究进展，分析其作用机制、药代动力学特点，并基于临床试验数据，比较其在糖尿病黄斑水肿治疗中的疗效、持久性、治疗周期及安全性，总结各药物的优势、劣势及适用人群，并展望未来的研究方向，以期为临床个体化治疗提供更为全面的参考依据。
Abstract: Diabetic retinopathy (DR) is the leading cause of blindness worldwide, and its incidence continues to rise, severely affecting patients’ vision and quality of life. Diabetic macular edema (DME) is the primary cause of visual impairment in patients with DR and involves complex pathophysiological mechanisms, in which vascular endothelial growth factor (VEGF) plays a pivotal role in the pathogenesis of both DR and DME. Therefore, exploring the latest developments in the application of anti-VEGF drugs is particularly important. This article aims to review recent research progress on anti-VEGF drugs in the treatment of DME, analyze their mechanisms of action and pharmacokinetic characteristics, and, based on clinical trial data, compare their efficacy, durability, treatment duration, and safety in the management of diabetic macular edema. It summarizes the advantages, disadvantages, and target patient populations of each drug and outlines future research directions, with the goal of providing a more comprehensive reference for personalized clinical treatment.
文章引用：孔越遆, 刘荣. 抗VEGF药物治疗糖尿病性黄斑水肿的 研究进展[J]. 临床医学进展, 2026, 16(7): 1310-1319. https://doi.org/10.12677/acm.2026.1672647

参考文献

[1] Subhi, Y., Potapenko, I., Hajari, J.N. and la Cour, M. (2023) Anti-VEGF Treatment of Diabetic Macular Edema in Denmark: Incidence, Burden of Therapy, and Forecasting Analyses. Journal of Personalized Medicine, 13, Article No. 546. [Google Scholar] [CrossRef] [PubMed]
[2] Andrés‐Blasco, I., Gallego‐Martínez, A., Palos, S.K., Lleó, A., Casaroli, R., Di Lauro, S., et al. (2024) Crosstalk between Oxidative Stress, Inflammation, Angiogenesis and Apoptosis in Diabetic Macular Edema. Acta Ophthalmologica, 102. [Google Scholar] [CrossRef] 
[3] Tatsumi, T. (2023) Current Treatments for Diabetic Macular Edema. International Journal of Molecular Sciences, 24, Article No. 9591. [Google Scholar] [CrossRef] [PubMed]
[4] Chauhan, M.Z., Rather, P.A., Samarah, S.M., Elhusseiny, A.M. and Sallam, A.B. (2022) Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema. Cells, 11, Article No. 1950. [Google Scholar] [CrossRef] [PubMed]
[5] Zhang, J., Zhang, J., Zhang, C., Zhang, J., Gu, L., Luo, D., et al. (2022) Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells, 11, Article No. 3362. [Google Scholar] [CrossRef] [PubMed]
[6] 吴学蕊, 林贞丽, 窦晓燕, 等. 抗VEGF药物治疗糖尿病黄斑水肿临床研究进展[J]. 深圳中西医结合杂志, 2017, 27(7): 187-190.
[7] 谭英, 冯卓蕾. 抗VEGF治疗眼底新生血管性疾病的临床研究进展[J]. 临床眼科杂志, 2023, 31(3): 274-278.
[8] Emami-Naeini, P., Garmo, V., Boucher, N., Fernando, R. and Menezes, A. (2025) Maintaining Driving Vision after Intravitreal Anti-VEGF Therapy in Patients with Neovascular AMD and Diabetic Macular Edema: A Plain Language Summary of Publication. Therapeutic Advances in Ophthalmology, 17, 1-10. [Google Scholar] [CrossRef] [PubMed]
[9] Ishibashi, R., Koshizaka, M., Takatsuna, Y., Tatsumi, T., Yamamoto, S. and Yokote, K. (2024) 16-OR: Preadministration of SGLT2 Inhibitor Reduces Frequency of Anti-Vegf Agent Administration in Patients with Mild Diabetic Macular Edema—A Multicenter Randomized Controlled Open-Label Trial. Diabetes, 73, 16-OR. [Google Scholar] [CrossRef] 
[10] Sakini, A.S.A., Hamid, A.K., Alkhuzaie, Z.A., Al-Aish, S.T., Al-Zubaidi, S., Tayem, A.A., et al. (2024) Diabetic Macular Edema (DME): Dissecting Pathogenesis, Prognostication, Diagnostic Modalities along with Current and Futuristic Therapeutic Insights. International Journal of Retina and Vitreous, 10, Article No. 83. [Google Scholar] [CrossRef] [PubMed]
[11] Khan, M., Aziz, A.A., Shafi, N.A., et al. (2020) Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab. Cells, 9, Article No. 1869.
[12] Chen-Li, G., Martinez-Archer, R., Coghi, A., Roca, J.A., Rodriguez, F.J., Acaba-Berrocal, L., et al. (2024) Beyond VEGF: Angiopoietin-Tie Signaling Pathway in Diabetic Retinopathy. Journal of Clinical Medicine, 13, Article No. 2778. [Google Scholar] [CrossRef] [PubMed]
[13] Foxton, R.H., Uhles, S., Grüner, S., Revelant, F. and Ullmer, C. (2019) Efficacy of Simultaneous VEGF‐A/ANG‐2 Neutralization in Suppressing Spontaneous Choroidal Neovascularization. EMBO Molecular Medicine, 11, EMMM201810204. [Google Scholar] [CrossRef] [PubMed]
[14] Hang, A., Feldman, S., Amin, A.P., Ochoa, J.A.R. and Park, S.S. (2023) Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders. Pharmaceuticals, 16, Article No. 1140. [Google Scholar] [CrossRef] [PubMed]
[15] Roberts, P.K., Vogl, W., Gerendas, B.S., Glassman, A.R., Bogunovic, H., Jampol, L.M., et al. (2020) Quantification of Fluid Resolution and Visual Acuity Gain in Patients with Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Ophthalmology, 138, Article No. 945. [Google Scholar] [CrossRef] [PubMed]
[16] Bressler, N.M., Odia, I., Maguire, M., Glassman, A.R., Jampol, L.M., MacCumber, M.W., et al. (2019) Association between Change in Visual Acuity and Change in Central Subfield Thickness during Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial. JAMA Ophthalmology, 137, Article No. 977. [Google Scholar] [CrossRef] [PubMed]
[17] Boz, A.A.E. (2024) Comparison of Costs of Bevacizumab, Ranibizumab, and Aflibercept in Loading Dose Administration for Diabetic Macular Edema Treatment: Observational Cost Analysis. European Eye Research, 4, 85-89. [Google Scholar] [CrossRef] 
[18] 刘佳, 蒋亚文, 倪惟一, 等. 抗VEGF类药物与传统激光疗法用于治疗糖尿病性黄斑水肿的药物经济学评价[J]. 中国药学杂志, 2020(5): 402-407.
[19] Mandava, N.K., Kuriyan, A.E., Ho, A.C., Hsu, J., Regillo, C.D. and Klufas, M.A. (2024) Enhanced Durability and Evolution of Retreatment Criteria of Intravitreal Antivascular Endothelial Growth Factor Agents for Diabetic Macular Edema. Current Opinion in Ophthalmology, 35, 197-204. [Google Scholar] [CrossRef] [PubMed]
[20] Liu, Z., Zheng, X. and Li, H. (2025) Recent Advances in the Study of Conbercept for Diabetic Macular Edema. International Journal of Retina and Vitreous, 11, Article No. 112. [Google Scholar] [CrossRef] 
[21] Mehta, H., Gabrielle, P., Hashimoto, Y., Kibret, G.D., Arnold, J., Guillaumie, T., et al. (2024) One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity. Ophthalmology Retina, 8, 872-879. [Google Scholar] [CrossRef] [PubMed]
[22] Kuo, B.L., Tabano, D., Garmo, V., et al. (2024) Long-Term Treatment Patterns for Diabetic Macular Edema. Ophthalmology Retina, 8, 1074-1082.
[23] Li, S., Pan, J., Xu, Y., Dai, Z. and Fang, Q. (2025) Exploring the Factors Influencing the Timely Intravitreal Anti-VEGF Treatment in Patients with Diabetic Macular Edema: A Qualitative Interview Study Using the COM-B Model. BMC Health Services Research, 25, Article No. 302. [Google Scholar] [CrossRef] [PubMed]
[24] 李晓蕊, 郭青龙, 卢娜. VEGFA/VEGFR2作用于血管内皮细胞途径及其抑制剂研究进展[J]. 药物生物技术, 2016, 23(3): 274-278.
[25] Liberski, S., Wichrowska, M. and Kocięcki, J. (2022) Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. International Journal of Molecular Sciences, 23, Article No. 9424. [Google Scholar] [CrossRef] [PubMed]
[26] 丁珊, 吴美初, 邢尧, 等. 玻璃体腔注射不同抗VEGF药物治疗糖尿病性黄斑水肿的有效性和安全性: 一项贝叶斯网状Meta分析[J]. 中医眼耳鼻喉杂志, 2023, 13(1): 1-6.
[27] Jhaveri, C.D., Glassman, A.R., Ferris, F.L., Liu, D., Maguire, M.G., Allen, J.B., et al. (2022) Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. New England Journal of Medicine, 387, 692-703. [Google Scholar] [CrossRef] [PubMed]
[28] Whitmore, J.R., Thompson, S.L. and Harrington, D. (2025) Efficacy of Intravitreal Anti-VEGF Agents in Diabetic Macular Edema: A Real-World Cohort Analysis. Advanced Journal of Biomedicine & Medicine, 13, 383-398. [Google Scholar] [CrossRef] 
[29] Yozgat, Z., Isik, M.U. and Sabaner, M.C. (2024) One-Year Outcomes of Aflibercept in Treat-and-Extend versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study. Ophthalmology and Therapy, 14, 169-181. [Google Scholar] [CrossRef] [PubMed]
[30] Bressler, S.B., Barve, A., Ganapathi, P.C., Beckmann, K., Apte, R.S., Marcus, D.M., et al. (2024) Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial. JAMA Ophthalmology, 142, Article No. 952. [Google Scholar] [CrossRef] [PubMed]
[31] Kashiwagi, I., Nonaka, R., Sasaki, S., Yamamoto, T., Yasuda, K. and Shimura, M. (2025) Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases. International Medical Case Reports Journal, 18, 465-471. [Google Scholar] [CrossRef] [PubMed]
[32] Fang, Y., Lai, I.P., Lai, T., Chen, T., Yang, C., Ho, T., et al. (2023) Long-Term Change in Renal Function after Intravitreal Anti-VEGF Treatment for Diabetic Macular Edema: A 2-Year Retrospective Cohort Study. Ophthalmology and Therapy, 12, 2977-2988. [Google Scholar] [CrossRef] [PubMed]
[33] Yao, J., Huang, W., Gao, L., et al. (2024) Comparative Efficacy of Anti-Vascular Endothelial Growth Factor on Diabetic Macular Edema Diagnosed with Different Patterns of Optical Coherence Tomography: A Network Meta-Analysis. PLOS ONE, 19, e0304283.
[34] 田涛, 姚晓喜, 彭婧利, 等. 不同抗VEGF药物治疗糖尿病性黄斑水肿的疗效及其与OCT分型的关系[J]. 国际眼科杂志, 2023, 23(6): 991-995.
[35] 安琪, 高健, 廖荣丰. 抗VEGF治疗糖尿病性黄斑水肿短期内黄斑区视网膜厚度光感受器层连续性及血流密度变化[J]. 安徽医学, 2020, 41(5): 515-518.
[36] 任晓慧, 高自清. OCTA观察糖尿病性黄斑水肿经抗VEGF治疗后黄斑区视网膜厚度和血流的变化[J]. 临床眼科杂志, 2020, 28(3): 202-205.
[37] 邱煦, 窦宏亮, 陈凤华. 玻璃体腔内注射抗VEGF药物治疗DME对黄斑区微循环的短期影响[J]. 国际眼科杂志, 2021, 21(8): 1473-1478.
[38] Chen, L., Chen, M. and Huang, W. (2025) Comparative Efficacy and Safety of Anti-VEGF Agents with and without Laser Therapy for Diabetic Macular Edema: A Network Meta-Analysis. European Journal of Ophthalmology, 35, 2347-2360. [Google Scholar] [CrossRef] [PubMed]
[39] CADTH (2023) Brolucizumab (Beovu). Canadian Journal of Health Technologies, 3, issue 2. [Google Scholar] [CrossRef] 
[40] 胡可可, 吴桐, 惠延年, 等. 新型小分子抗VEGF药物Brolucizumab治疗糖尿病性黄斑水肿的研究进展[J]. 国际眼科杂志, 2022, 22(8): 1277-1280.
[41] Rzyczniok, P. and Rasińska, A. (2025) Next-Generation Long-Acting Anti-VEGF Therapies for the Treatment of Diabetic Macular Edema. Quality in Sport, 40, Article No. 59606. [Google Scholar] [CrossRef] 
[42] Rübsam, A., Hössl, L., Rau, S., Böker, A., Zeitz, O. and Joussen, A.M. (2024) Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema. Journal of Clinical Medicine, 13, Article No. 1819. [Google Scholar] [CrossRef] [PubMed]
[43] Hirano, T., Kumazaki, A., Tomihara, R., Ito, S., Hoshiyama, K. and Murata, T. (2023) Evaluating Initial Responses to Brolucizumab in Patients Undergoing Conventional Anti-VEGF Therapy for Diabetic Macular Edema: A Retrospective, Single-Center, Observational Study. Scientific Reports, 13, Article No. 10901. [Google Scholar] [CrossRef] [PubMed]
[44] Agostini, H., Abreu, F., Baumal, C.R., Chang, D.S., G. Csaky, K., Demetriades, A.M., et al. (2024) Faricimab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: From Preclinical Studies to Phase 3 Outcomes. Graefe’s Archive for Clinical and Experimental Ophthalmology, 262, 3437-3451. [Google Scholar] [CrossRef] [PubMed]
[45] Ferro Desideri, L., Traverso, C.E., Nicolò, M. and Munk, M.R. (2023) Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration. Pharmaceutics, 15, Article No. 1413. [Google Scholar] [CrossRef] [PubMed]
[46] Zolotarev, A.V., Karlova, E.V., Balandina, E.V., Zubkova, E.Y., Grishina, E.E., Zamytskiy, E.A., et al. (2024) Dual Inhibition of VEGF-A and Angiopoietin-2 in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Russian Annals of Ophthalmology, 140, Article No. 100. [Google Scholar] [CrossRef] [PubMed]
[47] Shimura, M., Kitano, S., Ogata, N., Mitamura, Y., Oh, H., Ochi, H., et al. (2023) Efficacy, Durability, and Safety of Faricimab with Extended Dosing Up to Every 16 Weeks in Japanese Patients with Diabetic Macular Edema: 1-Year Results from the Japan Subgroup of the Phase 3 YOSEMITE Trial. Japanese Journal of Ophthalmology, 67, 264-279. [Google Scholar] [CrossRef] [PubMed]
[48] Murao, F., Yanai, R., Kusuhara, S., Abe, Y., Shimura, M., Ohara, H., et al. (2025) Visual Outcomes and Anatomical Biomarkers of Faricimab for Diabetic Macular Edema in the J-CREST Real-World Comparison of Naïve and Treated Eyes. Scientific Reports, 15, Article No. 36628. [Google Scholar] [CrossRef] 
[49] Pichi, F., Abdi, A., Aljneibi, S., El Ghrably, I., Agarwal, A. and Ghazi, N.G. (2024) Switch to Faricimab after Initial Treatment with Aflibercept in Eyes with Diabetic Macular Edema. International Ophthalmology, 44, Article No. 275. [Google Scholar] [CrossRef] [PubMed]
[50] Huber, K.L., Stino, H., Steiner, I., Fuchs, P., Goldbach, F., Mai, J., et al. (2024) Real-World Outcomes after Switch from Aflibercept to Faricimab in Eyes with Diabetic Macular Edema. Investigative Ophthalmology & Visual Science, 65, Article No. 46. [Google Scholar] [CrossRef] [PubMed]
[51] Shimura, M., Sasaki, S., Nonaka, R., Kashiwagi, I., Yasuda, K., Noma, H., et al. (2024) Changes in Aqueous Angiopoietin-1/2 Concentrations during the Induction Phase of Intravitreal Faricimab Injections for Diabetic Macular Edema. Translational Vision Science & Technology, 13, Article No. 35. [Google Scholar] [CrossRef] [PubMed]
[52] Watkins, C., Paulo, T., Bührer, C., Holekamp, N.M. and Bagijn, M. (2023) Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis. Advances in Therapy, 40, 5204-5221. [Google Scholar] [CrossRef] [PubMed]
[53] Shimura, M., Kitano, S., Muramatsu, D., Fukushima, H., Takamura, Y., Matsumoto, M., et al. (2019) Real-World Management of Treatment-Naïve Diabetic Macular Oedema in Japan: Two-Year Visual Outcomes with and without Anti-VEGF Therapy in the STREAT-DME Study. British Journal of Ophthalmology, 104, 1209-1215. [Google Scholar] [CrossRef] [PubMed]

为你推荐